Gregory James Kato MD (He/Him)

Sickle Cell & Other Anemias

Executive Director, Global Product Lead, Hematology Therapeutic Area

CSL Behring1020 First AveKing of Prussia, PA 19406
Phone+1 610-290-7452
Fax+1 610-290-0452

Dr. Kato is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kato's full profile Already have an account?

Summary

I am a hematologist with an active translational research interest in sickle cell disease, especially how intravascular hemolysis affects the complications of sickle cell disease. My past research experience includes blood flow physiology studies, clinical trials and proteomic analysis of plasma to unravel new mechanisms contributing to pulmonary hypertension and other complications of sickle cell disease. We have formulated a model to suggest that pulmonary hypertension, stroke, leg ulcers and priapism share features of vasculopathy.

After 29 years of patient care, clinical research and molecular biology laboratory research, I have taken a role in the biotech industry to develop new therapeutics for sickle cell disease and other blood disorders.

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Children's Hospital Los AngelesResidency, Pediatrics, 1985 - 1988
George Washington University School of Medicine and Health SciencesClass of 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 2013 - 2022
MD State Medical License 1988 - 2014
DC State Medical License 2003 - 2008

Clinical Trials

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases Start of enrollment: 2017 Apr 11
COMPLETED
PHASE2
Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers Start of enrollment: 2018 Apr 06
TERMINATED
PHASE2

Publications & Presentations

PubMed

1 citations
Targeted Proteomic Analysis of Sickle Cell Disease Patients With Elevated Tricuspid Regurgitation Velocity.
Varshini Babu, Jane A Little, Claudia R Morris, Roberto Machado, Simon Gibbs
Proteomics. Clinical Applications. 2025-09-01
8 citations
Hemoglobin scavenger receptor CD163 as a potential biomarker of hemolysis-induced hepatobiliary injury in sickle cell disease.
Tomasz W Kaminski, Ayyanar Sivanantham, Anna Mozhenkova, Ashley Smith, Ramakrishna Ungalara
American Journal of Physiology. Cell Physiology. 2024-08-01
10 citations
Iron restriction in sickle cell disease: When less is more.
Oswaldo L Castro, Lucia De Franceschi, Tomas Ganz, Julie Kanter, Gregory J Kato
American Journal of Hematology. 2024-07-01

Journal Articles

Clinical Outcomes Associated with Sickle Cell Trait: A Systematic Review
Kathryn L Hassell, Rakhi P Naik, Puneet Sahota, Gregory J Kato, Clinton H Joiner, Annals of Internal Medicine
Simultaneous Polymerization and Adhesion Under Hypoxia in Sickle Cell Disease
Gregory Kato, MD, Proceedings of the National Academy of Sciences
Abstract Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional Feasibility Study
Gregory Kato, Nirmish Shah, Ajay Wasan, JMIR Medical Education

Abstracts/Posters

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Ear...
Gregory J Kato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Nrf2 Null Mice Are Deficient in CD169+ Macrophages, Associated with Impaired Erythroid Response and Delayed Recovery from Acute Blood Loss
Gregory J Kato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Pria...
Gregory J Kato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Disease Modification in Sickle Cell Disease: Mechanisms, Advances and Clinical Implications
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Sickle Cell DiseaseApril 2021
Sickle Cell DiseaseMarch 2018

Grant Support

Use Of Hydroxyurea &L-Arginine Or Sildenafil In Patients W/Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2011
Treatment Of PH And SCD With Sildenafil TherapyNational Heart, Lung, And Blood Institute2009–2011
Therapeutic Application Of Intravascular Nitrite For Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2011
Systemic Nitrite Infusion And Its Effect On Exercise Physiology And MetabolismNational Heart, Lung, And Blood Institute2009–2011
Synergy Of Hydroxyurea And Erythropoietin On Fetal Hemoglobin In SCDNational Heart, Lung, And Blood Institute2009–2011

Professional Memberships

American Society of Hematology - ASH
Member

Other Languages

Spanish

Industry Relationships

Executive Director, Global Product Lead, CSLGlobal Product Lead for the Hematology Therapeutic Area, currently leading the development of CSL889 Hemopexin and Vamifeport for sickle cell disease and CSL888 Haptoglobin for subarachnoid hemorrhage.Disclosure: Full time employee and equity shareholder2020 - Present
Consultant, Biogen IdecDisclosure: Consulting fee2014 - 2015